June 17, 2020 / 12:29 PM / a month ago

BRIEF-Outlook Therapeutics Provides Clinical Update On ONS-5010 / LYTENAVA

June 17 (Reuters) - Outlook Therapeutics Inc:

* OUTLOOK THERAPEUTICS PROVIDES CLINICAL UPDATE ON ONS-5010 / LYTENAVA™ (BEVACIZUMAB-VIKG)

* OUTLOOK THERAPEUTICS INC - TOPLINE RESULTS FROM NORSE 1, EVALUATING ONS-5010 ARE EXPECTED IN AUGUST 2020

* OUTLOOK THERAPEUTICS INC - NORSE 2 EXPECTED TO COMPLETE ENROLLMENT NO LATER THAN AUGUST 2020

* OUTLOOK THERAPEUTICS INC - NORSE 3 OPEN-LABEL SAFETY STUDY DESIGNED TO SUPPORT PLANNED BLA IS EXPECTED TO COMMENCE IN Q4 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below